Without knowing exactly what that report says there was a...

Without knowing exactly what that report says there was a comment in HC from RBS last week that Fonda revenue was increasing each month at a steady rate (or words to that effect). If you look back to the RBS analysts reports from 2012 they had valued Fonda at 0.60 and the Biotech part of ACL at 0.29 ($80m) for a total valuation of 0.89. So if Fonda is tracking nicely that value of 0.60 may be firming up (maybe some dilution from the latest capital raise) and if we have a potential for income via Astra Zenica, as well as Europe, Fonda revenue coming on stream and Audeo/phase III value still to be determined, I think we are in a damn great position.

Also what a great week to make an announcement with everyone getting their cap raising refunds.